Alvotech files 6-K

Alvotech raised approximately $91.20 million in net proceeds from a public offering of ordinary shares and an additional $66.85 million from a private placement of ordinary shares. The company also received Complete Response Letters from the FDA for its Biologics License Applications (BLAs) for AVT03, AVT05, and AVT06, citing deficiencies related to its Reykjavik manufacturing facility.